Antisense oligonucleotides: From design to therapeutic application

被引:327
作者
Chan, JHP
Lim, SH
Wong, WSF
机构
[1] Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Singapore 117597, Singapore
[2] Natl Univ Singapore, Immunol Program, Singapore 117597, Singapore
关键词
antisense oligonucleotide design; cell-penetrating peptide; dendrimer; gapmer antisense oligonucleotide; liposome; locked nucleic acid; peptide nucleic acid; phosphoroamidate morpholino oligomer; phosphorothioate; RNase H;
D O I
10.1111/j.1440-1681.2006.04403.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. An antisense oligonucleotide (ASO) is a short strand of deoxyribonucleotide analogue that hybridizes with the complementary mRNA in a sequence-specific manner via Watson-Crick base pairing. Formation of the ASO-mRNA heteroduplex either triggers RNase H activity, leading to mRNA degradation, induces translational arrest by steric hindrance of ribosomal activity, interferes with mRNA maturation by inhibiting splicing or destabilizes pre-mRNA in the nucleus, resulting in downregulation of target protein expression. 2. The ASO is not only a useful experimental tool in protein target identification and validation, but also a highly selective therapeutic strategy for diseases with dysregulated protein expression. 3. In the present review, we discuss various theoretical approaches to rational design of ASO, chemical modifications of ASO, ASO delivery systems and ASO-related toxicology. Finally, we survey ASO drugs in various current clinical studies.
引用
收藏
页码:533 / 540
页数:8
相关论文
共 61 条
  • [21] Antisense therapy for cancer
    Gleave, ME
    Monia, BP
    [J]. NATURE REVIEWS CANCER, 2005, 5 (06) : 468 - 479
  • [22] Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries
    Ho, SP
    Britton, DHO
    Stone, BA
    Behrens, DL
    Leffet, LM
    Hobbs, FW
    Miller, JA
    Trainor, GL
    [J]. NUCLEIC ACIDS RESEARCH, 1996, 24 (10) : 1901 - 1907
  • [23] Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
    Ho, SP
    Bao, YJ
    Lesher, T
    Malhotra, R
    Ma, LY
    Fluharty, SJ
    Sakai, RR
    [J]. NATURE BIOTECHNOLOGY, 1998, 16 (01) : 59 - 63
  • [24] Iversen PL, 2003, CLIN CANCER RES, V9, P2510
  • [25] The use of cell-penetrating peptides as a tool for gene regulation
    Järver, P
    Langel, Ü
    [J]. DRUG DISCOVERY TODAY, 2004, 9 (09) : 395 - 402
  • [26] Toxicology of antisense therapeutics
    Jason, TLH
    Koropatnick, J
    Berg, RW
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2004, 201 (01) : 66 - 83
  • [27] Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates
    Kaihatsu, K
    Huffman, KE
    Corey, DR
    [J]. BIOCHEMISTRY, 2004, 43 (45) : 14340 - 14347
  • [28] Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes:: in vitro and in vivo studies
    Khan, A
    Benboubetra, M
    Sayyed, PZ
    Ng, KW
    Fox, S
    Beck, G
    Benter, IF
    Akhtar, S
    [J]. JOURNAL OF DRUG TARGETING, 2004, 12 (06) : 393 - 404
  • [29] Cellular delivery of peptide nucleic acid (PNA)
    Koppelhus, U
    Nielsen, PE
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (02) : 267 - 280
  • [30] KRETSCHMERKAZEM.FR, 2001, BIOINFORMATICS, V17, P1058